BlueJay Therapeutics is focused on developing innovative treatments for chronic hepatitis B (CHB) and chronic hepatitis D (CHD), aiming to shift the current treatment paradigms for these viral liver diseases. Their lead program, BJT-778, is a monoclonal antibody designed to significantly reduce hepatitis B surface antigen (HBsAg) levels, which can help alleviate immune cell exhaustion and enable the immune system to better control the infection. Additionally, the company is advancing Cavrotolimod, a toll-like receptor 9 (TLR9) agonist that aims to stimulate both innate and adaptive immune responses, and BJT-628, an orally bioavailable small molecule that targets HBV transcripts to reduce HBsAg production.

BlueJay Therapeutics also emphasizes its proprietary Liver-Targeting Advanced Platform (L-TAP), which allows for the precise delivery of oral small molecules directly to the liver. This technology enhances the efficacy of treatments while minimizing exposure to other sensitive tissues, thereby improving safety profiles. The company is committed to addressing the significant unmet medical needs in the field of viral and liver diseases, with a pipeline that includes potential best-in-class therapies for CHB and CHD, as well as novel agents for other prevalent liver conditions.

United States

The mission of Bluejay Therapeutics is to develop innovative cures for infectious diseases with the first target indication of chronic HBV infection. Bluejay has exclusively licensed global rights to advance several HBV programs, including a best-in-class anti-HBsAg monoclonal antibody.

BlueJay Therapeutics

Company Details